Kanghong Biotech
康弘生物
Executive Summary
Kanghong Biotech (002773.SZ) is a profitable Chengdu-based biotech company with strong financial performance, reporting RMB 3.4B revenue and RMB 974M net profit in 2024. The company has demonstrated international deal-making experience through partnerships with global CROs like INC Research, suggesting readiness for cross-border collaborations. With clear BIOSECURE status, this represents a lower-risk Chinese biotech partner for US pharma companies seeking Asian market access or pipeline assets.
Structure: Limited public information suggests a straightforward structure as a Shenzhen-listed entity (002773.SZ) based in Chengdu. The company appears to operate through subsidiary structures including Chengdu Kanghong Biotechnology Co., Ltd., though detailed ownership layers require further due diligence to confirm VIE arrangements typical of Chinese biotech companies.
Latest Financials
Revenue: 3411293193.61, Net Profit: 973711578.04. Source: East Money (002773)
Period: 2024-09-30 | Source: eastmoney
Corporate Events
Kanghong Biotech Financial Report
Revenue: 3411293193.61, Net Profit: 973711578.04. Source: East Money (002773)
康弘药业：关于成都康弘生物科技有限公司拟聘请INC Research, LLC.提供临床试验研究服务的公告
CNINFO announcement for Kanghong Biotech (002773.SZ)
BIOSECURE Risk
Company has clear BIOSECURE status with no BCC designation, reducing regulatory compliance concerns for US partnerships
Key Exposures:
- •Standard Chinese entity risks
- •Potential future regulatory changes
Mitigation: Currently clear of BIOSECURE restrictions with no apparent exposure to designated entities
BD Intelligence
Therapeutic Areas:
Recent Deals: Historical engagement with INC Research for clinical trial services demonstrates comfort with international partnerships and regulatory standards
Approach: Approach as a financially stable partner with proven international collaboration experience; focus on pipeline asset evaluation and China market access opportunities
Red Flags
- ⚠Limited public disclosure of pipeline assets and therapeutic focus
- ⚠Insufficient key personnel information for relationship mapping
- ⚠Subsidiary structure requires detailed due diligence
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 2
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 0
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.